Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2020 | State of the art in CAR-T

Peter Riedell • 25 Sep 2020
SOHO 2020
Lymphoma CAR-T Ibrutinib

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an outlook in the current CAR-T climate and where things are moving towards in the future, including a better understanding of response, T-cell exhaution and CD19 antigen loss. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Peter Riedell

Real-world outcomes of liso-cel therapy in R/R DLBCL 1:19
Real-world outcomes of liso-cel therapy in R/R DLBCL
Peter Riedell • 11 Dec 2023
An overview of CAR-T therapy in DLBCL and MCL 3:42
An overview of CAR-T therapy in DLBCL and MCL
Peter Riedell • 27 Apr 2022
Latest updates in CAR-T therapy for follicular lymphoma 1:53
Latest updates in CAR-T therapy for follicular lymphoma
Peter Riedell • 27 Apr 2022
Autologous transplantation followed by maintenance vs maintenance alone in patients with MCL 2:04
Autologous transplantation followed by maintenance vs maintenance alone in patients with MCL
Peter Riedell • 27 Apr 2022

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals